InventisBio

Small-molecule pharma (private)

688382 · SSE STAR Market · China

Public Market Listing

688382SSE STAR Market

SSE STAR Market primary exchange listing

Live quotes, historical charts, and market capitalization for InventisBio are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(4 total)
4Total Assets
0Approved
4Phase 3 / Filed
0Phase 1–2 / Early
6Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 3
EGFRSmall molecule
Non-Small Cell Lung Cancer
Garsorasib(Anfangning)
Phase 3
KRAS G12CSmall molecule
Non-Small Cell Lung Cancer
Phase 3
TYK2Small molecule
Inflammatory Bowel DiseasePsoriasisSystemic Lupus ErythematosusVitiligo
Ulcerative Colitis
Phase 3
Estrogen receptorSmall molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
TaragarestrantPhase 3Breast Cancer
Est. primary completion 2026-11-30 · NCT06954961 · CT.gov ↗
What to watch
2027 (6)
July 2027 (2)
Nomelcitinib (D-2570)Phase 3Plaque Psoriasis
Est. primary completion 2027-07-12 · NCT07326813 · CT.gov ↗
What to watch
Nomelcitinib (D-2570)Phase 3Plaque Psoriasis
Est. primary completion 2027-07-28 · NCT07130604 · CT.gov ↗
What to watch
August 2027 (2)
Nomelcitinib (D-2570)Phase 2Psoriasis
Est. primary completion 2027-08 · NCT07489885 · CT.gov ↗
What to watch
Nomelcitinib (D-2570)Phase 2PsA (Psoriatic Arthritis)
Est. primary completion 2027-08-15 · NCT07315061 · CT.gov ↗
What to watch
November 2027 (1)
Nomelcitinib (D-2570)Phase 2Vitiligo, Non-Segmental Vitiligo (NSV)
Est. primary completion 2027-11 · NCT07625891 · CT.gov ↗
What to watch
December 2027 (1)
Garsorasib · AnfangningPhase 1/2Solid Tumor
Est. primary completion 2027-12-31 · NCT05379946 · CT.gov ↗
What to watch
2028 (3)
April 2028 (1)
BefotertinibPhase 3Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
Est. primary completion 2028-04-30 · NCT06041776 · CT.gov ↗
What to watch
August 2028 (1)
Nomelcitinib (D-2570)Phase 2Active Systemic Lupus Erythematosus
Est. primary completion 2028-08-31 · NCT07311200 · CT.gov ↗
What to watch
November 2028 (1)
BefotertinibPhase 2NSCLC, Adjuvant Drug Therapy, EGFR
Est. primary completion 2028-11 · NCT07181499 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 November 2026Topline resultD-2570Phase 3 of nomelcitinib (D-2570) met its primary endpoint in plaque psoriasis
9 March 2025Topline resultNomelcitinib (D-2570)Phase II topline results of D-2570 in plaque psoriasis

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-H1$7.8M$27M$173M$10.0Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$5.2M$45M$197M$11Mreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$23M$53M$217M$8.4Mreport ↗
2023-FY$26M$63M$270M$10Mreport ↗
2022-FY$0$69M$321M$18Mreport ↗
2021-FY$0$49M$114M$14Mreport ↗